Real-World Outcomes and Sequencing in Metastatic Colorectal Cancer

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.